Primrose Bio
Simon Latimer currently serves as the Chief Financial Officer at Primrose Bio, a role initiated in November 2023. Prior to this, Simon held various positions at Ligand Pharmaceuticals from August 2019 to November 2023, culminating in the role of Director of Strategic Planning & Investor Relations. Simon’s earlier career includes extensive experience at Ernst & Young, providing assurance services related to the life sciences industry, with a focus on IPOs and public company reporting. Simon also contributed to Koch Industries as an Accounting/Analyst where VBA coding was employed to enhance reporting efficiency. Simon holds a Master's degree in Accountancy and an Associate's degree in Health Economics from the University of Denver.
Primrose Bio
Primrose Bio offers radically new products and tools that unlock unexplored possibilities for the discovery, development, and manufacturing of new molecules. Our mission is to enable the development of innovative therapeutics, vaccines and ingredients to advance global health.